Study summary

An antibody that clears amyloid deposits missed its main goal but helped one subtype

CARES trials (anselamimab) · 406 people, two phase 3 trials · Published May 2026, Journal of Clinical Oncology

62%lower risk of death in kappa-type disease

What was tested

Anselamimab (CAEL-101), an antibody designed to help clear amyloid deposits from the heart, added to standard treatment, against placebo, for advanced (Mayo stage IIIa/IIIb) AL amyloidosis.

What they found

Across everyone, the main combined goal was not met (win ratio 1.11).
In people with kappa-type light chains, risk of death fell 62% and heart-related hospitalizations 71%.
No benefit was seen in lambda-type disease.

What it means

The first sign that removing existing amyloid, not just stopping new production, can help, though only in a subgroup so far.

J Clin Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.